Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Alprazolam
Drug ID BADD_D00085
Description Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms.[A18125] Alprazolam's adverse effects are generally related to the sedation it can cause.[A18125] Alprazolam has been mixed with alcohol as a drug of abuse to potentiate the sedative effects of the drug which may lead to coma and death.[A18125] Alprazolam was given FDA approval on October 16, 1981.[L6148]
Indications and Usage For the management of anxiety disorder or the short-term relief of symptoms of anxiety and for the treatment of panic disorder, with or without agoraphobia.
Marketing Status Prescription; Discontinued
ATC Code N05BA12
DrugBank ID DB00404
KEGG ID D00225
MeSH ID D000525
PubChem ID 2118
TTD Drug ID D0L9GG
NDC Product Code 71335-1092; 12828-0040; 72189-029; 70954-511; 71335-1576; 0781-1061; 71335-1386; 53002-3950; 61919-836; 0009-0094; 65862-676; 53002-0340; 60760-550; 0228-4019; 72789-024; 0228-3086; 68071-4855; 50090-5257; 72789-087; 72189-058; 50090-5262; 0228-2039; 65862-677; 70954-510; 53002-4181; 68071-5243; 0615-8216; 68788-7594; 80425-0100; 63629-7726; 65162-812; 65862-456; 71335-1669; 61919-379; 71335-0849; 0228-2027; 72789-151; 55154-5885; 65862-679; 50090-5258; 72189-213; 65162-813; 55700-671; 50090-1759; 72189-240; 57218-312; 72789-042; 0228-2029; 71335-1894; 0781-1089; 71335-1839; 71335-1291; 71610-113; 45865-424; 70954-508; 61919-005; 71205-284; 68071-4818; 51991-705; 71335-0920; 65162-810; 80425-0110; 50090-5078; 59762-3721; 63187-971; 68788-7595; 51991-707; 72189-121; 0009-0066; 53002-3952; 64980-398; 59762-0059; 66267-564; 71335-1477; 42816-0090; 67296-0958; 65862-678; 53002-4180; 0228-3083; 0904-5860; 63187-518; 45865-993; 65862-455; 0054-3068; 65862-457; 60429-504; 68788-7596; 67544-347; 63629-8164; 0009-0057; 50090-4950; 61919-849; 49999-032; 64980-399; 0228-4024; 0228-2031; 70934-558; 63629-8172; 67544-414; 71205-614; 49884-214; 55289-523; 68071-4621; 0009-5144; 71335-1129; 63187-445; 65862-454; 59762-0066; 80425-0161; 71205-386; 68788-9682; 68071-4652; 70934-815; 51991-706; 0009-0068; 70518-3259; 59762-3719; 43063-609; 80425-0099; 0228-3084; 0228-4025; 59762-3720; 61919-576; 0009-0055; 68071-2236; 63629-8214; 12780-4630; 64980-396; 67253-901; 0781-1077; 67253-902; 64980-397; 68071-4923; 68071-5263; 71335-0813; 71205-227; 50090-5109; 42816-0029; 49999-252; 71610-112; 49884-110; 71335-0680; 63187-443; 0228-3087; 65162-809; 67253-900; 63187-225; 71554-013; 67253-903; 71205-290; 70518-2870; 55700-929; 35356-744; 65015-634; 0781-1079; 59762-0057; 71205-652; 59762-0068; 42816-0055; 0009-0029; 51991-704; 45865-972; 68071-5128; 68071-2220; 0009-0090; 63187-916; 67296-1748; 49452-0295; 71335-0673; 49884-213; 68071-4831; 63187-966; 0009-0059; 50090-5261; 63187-444; 50090-2781; 55700-312; 71335-1907; 59762-3722; 70954-509; 64330-013; 71335-0427; 0228-4022; 68788-7613; 68071-5113; 67544-415; 70518-2785; 0615-8295; 51655-266; 49884-111
Synonyms Alprazolam | Alprazolan | Trankimazin | U-31,889 | U31,889 | Xanax | Alprox | Esparon | Cassadan | D-65MT | D65MT | Kalma | Novo-Alprazol | Novo Alprazol | Nu-Alpraz | Nu Alpraz | Ralozam | Tafil | Apo-Alpraz | Apo Alpraz
Chemical Information
Molecular Formula C17H13ClN4
CAS Registry Number 28981-97-7
SMILES CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Anterograde amnesiaPlatelet-activating factor receptorP25105T870239467187; 12798263; 9500121; 10803407; 9698157; 1668111; 14723318; 11968060
Anterograde amnesiaTranslocator proteinP30536T754409467187; 12798263; 9500121; 10803407; 9698157; 1668111; 14723318; 11968060
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Haemoglobin13.01.05.018--Not Available
Haemoglobin decreased13.01.05.003--Not Available
Hallucination19.10.02.0020.001129%
Hallucination, auditory19.10.02.003--Not Available
Hallucination, visual19.10.02.004--Not Available
Hallucinations, mixed19.10.02.0070.000209%Not Available
Hangover08.01.09.018--Not Available
Head discomfort17.02.05.0270.000125%Not Available
Headache17.14.01.001--
Heart rate decreased13.14.04.001--Not Available
Heart rate increased13.14.04.0020.000794%Not Available
Heart rate irregular13.14.04.003--Not Available
Heat stroke24.06.02.009; 12.05.01.0010.000022%Not Available
Hemiplegia17.01.04.002--Not Available
Hepatic cirrhosis09.01.04.001--Not Available
Hepatic failure09.01.03.0020.000836%
Hepatic function abnormal09.01.02.001--Not Available
Hepatitis09.01.07.0040.000293%Not Available
Hepatitis acute09.01.07.0050.000251%Not Available
Hepatitis cholestatic09.01.01.0020.000543%Not Available
Hepatitis fulminant11.07.01.003; 09.01.07.0070.000120%Not Available
Hepatitis toxic12.03.01.016; 09.01.07.0170.000167%Not Available
Hepatocellular injury09.01.07.0080.002257%Not Available
Hepatomegaly09.01.05.0010.000125%Not Available
Hepatosplenomegaly09.01.05.002; 01.09.03.0010.000084%Not Available
Hepatotoxicity12.03.01.008; 09.01.07.0090.000543%Not Available
Hostility19.05.01.0030.000084%Not Available
Hunger14.03.02.012; 08.01.09.0030.000084%Not Available
Hyperaesthesia17.02.06.0040.000084%Not Available
Hyperammonaemia14.10.01.001; 09.01.02.0020.000125%Not Available
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 25 Pages